CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-21 | Mutz Christopher HEAD OF RARE DISEASE | Sale | −2,000 | $61.61 | $123K | 83,277 |
| 2024-05-20 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −12,855 | $61.81 | $795K | 732,620 |
| 2024-05-17 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −5,836 | $62.09 | $362K | 745,475 |
| 2024-05-16 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −16,459 | $63.84 | $1.1M | 751,311 |
| 2024-05-16 | TANNENBAUM RENEE P Director | Sale | −2,000 | $63.87 | $128K | 18,211 |
| 2024-05-15 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −14,850 | $65.86 | $978K | 767,770 |
| 2024-05-14 | Lalwani Nikhil PRESIDENT & CEO | Sale | −16,669 | $66.10 | $1.1M | 377,505 |
| 2024-05-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −250 | $67.69 | $17K | 59,481 |
| 2024-05-01 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $66.62 | $1.3M | 233,226 |
| 2024-04-19 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −16,809 | $65.17 | $1.1M | 782,620 |
| 2024-04-18 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −10,423 | $64.98 | $677K | 799,429 |
| 2024-04-17 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −9,520 | $65.40 | $623K | 809,852 |
| 2024-04-16 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −5,834 | $66.20 | $386K | 819,372 |
| 2024-04-15 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −7,414 | $66.33 | $492K | 825,206 |
| 2024-04-12 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −250 | $67.79 | $17K | 59,731 |
| 2024-04-10 | CAREY STEPHEN P. SVP & CFO | Shares withheld for taxes | −4,534 | $66.96 | $304K | 166,968 |
| 2024-04-10 | Marken James G. SVP OPS & PROD DEV | Shares withheld for taxes | −2,799 | $66.96 | $187K | 116,006 |
| 2024-04-01 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $67.25 | $1.3M | 253,226 |
| 2024-03-23 | Lalwani Nikhil PRESIDENT & CEO | Shares withheld for taxes | −17,455 | $69.58 | $1.2M | 394,174 |
| 2024-03-23 | CAREY STEPHEN P. SVP & CFO | Shares withheld for taxes | −6,210 | $69.58 | $432K | 171,502 |
Page 13 of 23 · 442 trades